Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin⁺ cell abundance

References

• Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstrom PU, Choi W, Guo CC, Lotan Y, Kassouf W. Bladder cancer. Lancet. [Journal Article; Review]. 2016;388(10061):2796–9. doi:10.1016/S0140-6736(16)30512-8.
   PubMed Web of Science ®Google Scholar
• Alfred Witjes J, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, Hernández V, Espinós EL, Dunn J, Rouanne M, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71(3):462–475. doi:10.1016/j.eururo.2016.06.020.
   PubMed Web of Science ®Google Scholar
• Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL, Choueiri TK, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014;66(1):42–54. doi:10.1016/j.eururo.2013.08.033.
   PubMed Web of Science ®Google Scholar
• Alifrangis C, McGovern U, Freeman A, Powles T, Linch M. Molecular and histopathology directed therapy for advanced bladder cancer. Nat Rev Urol. [Journal Article; Review]. 2019;16(8):465–483. doi:10.1038/s41585-019-0208-0.
   PubMed Web of Science ®Google Scholar
• Felsenstein KM, Theodorescu D. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. Nat Rev Urol. 2018;15(2):92–111. doi:10.1038/nrurol.2017.179.
   PubMed Web of Science ®Google Scholar
• Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. [Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov’t]. 2019 Jul 25;381(4):338–348. doi:10.1056/NEJMoa1817323.
   PubMed Web of Science ®Google Scholar
• Powles T, Huddart RA, Elliott T, Sarker S, Ackerman C, Jones R, Hussain S, Crabb S, Jagdev S, Chester J, et al. Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2–positive metastatic bladder cancer. J Clin Oncol. 2017;35(1):48–55. doi:10.1200/JCO.2015.66.3468.
   PubMed Web of Science ®Google Scholar
• Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm M-O, Bracarda S et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Jan 01;18(3):312–322. doi:10.1016/S1470-2045(17)30065-7.
   PubMed Web of Science ®Google Scholar
• Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76. doi:10.1016/S0140-6736(16)32455-2.
   PubMed Web of Science ®Google Scholar
• Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. [Journal Article]. 2017 oct 19;171(3):540–556. doi:10.1016/j.cell.2017.09.007.
   PubMed Web of Science ®Google Scholar
• Kamoun A, de Reynies A, Allory Y, Sjodahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. [Journal Article]. 2020 Apr 01;77(4):420–433. doi:10.1016/j.eururo.2019.09.006.
   Web of Science ®Google Scholar
• Pan Y, Yago T, Fu J, Herzog B, McDaniel JM, Mehta-D’Souza P, Cai X, Ruan C, McEver RP, West C, et al. Podoplanin requires sialylated O-glycans for stable expression on lymphatic endothelial cells and for interaction with platelets. Blood. [Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov’t; Research Support, U.S. Gov’t, Non-P.H.S.]. 2014 Dec 04;124(24):3656–3665. doi:10.1182/blood-2014-04-572107.
   PubMed Web of Science ®Google Scholar
• Astarita JL, Acton SE, Turley SJ. Podoplanin: emerging functions in development, the immune system, and cancer. Front Immunol. 2012;3:283. doi:10.3389/fimmu.2012.00283.
   Web of Science ®Google Scholar
• Bieniasz-Krzywiec P, Martín-Pérez R, Ehling M, García-Caballero M, Pinioti S, Pretto S, Kroes R, Aldeni C, Di Matteo M, Prenen H, et al. Podoplanin-expressing macrophages promote lymphangiogenesis and lymphoinvasion in breast cancer. Cell Metab. 2019;30(5):917–936. doi:10.1016/j.cmet.2019.07.015.
   PubMed Web of Science ®Google Scholar
• Eisemann T, Costa B, Peterziel H, Angel P. Podoplanin positive myeloid cells promote glioma development by immune suppression. Front Oncol. 2019 Jan 20;9:187. doi:10.3389/fonc.2019.00187.
   PubMed Web of Science ®Google Scholar
• Nylander AN, Ponath GD, Axisa P, Mubarak M, Tomayko M, Kuchroo VK, Pitt D, Hafler DA. Podoplanin is a negative regulator of Th17 inflammation. JCI Insight. 2017 Jan 01;2(17). doi:10.1172/jci.insight.92321.
   PubMed Web of Science ®Google Scholar
• Chihara N, Madi A, Kondo T, Zhang H, Acharya N, Singer M, Nyman J, Marjanovic ND, Kowalczyk MS, Wang C, et al. Induction and transcriptional regulation of the co-inhibitory gene module in T cells. NATURE. 2018;558(7710):454–459. doi:10.1038/s41586-018-0206-z.
   PubMed Web of Science ®Google Scholar
• Fu Q, Xu L, Wang Y, Jiang Q, Liu Z, Zhang J, Zhou Q, Zeng H, Tong S, Wang T, et al. Tumor-associated macrophage-derived interleukin-23 interlinks kidney cancer glutamine addiction with immune evasion. Eur Urol. 2019;75(5):752–763. doi:10.1016/j.eururo.2018.09.030.
   PubMed Web of Science ®Google Scholar
• Afonso J, Santos LL, Amaro T, Lobo F, Longatto-Filho A. The aggressiveness of urothelial carcinoma depends to a large extent on lymphovascular invasion–the prognostic contribution of related molecular markers. Histopathology. [Journal Article; Research Support, Non-U.S. Gov’t]. 2009;55(5):514–524. doi:10.1111/j.1365-2559.2009.03425.x.
   PubMed Web of Science ®Google Scholar
• Sjodahl G, Lauss M, Lovgren K, Chebil G, Gudjonsson S, Veerla S, Patschan O, Aine M, Ferno M, Ringner M et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012 Jun 15;18(12):3377–3386. doi:10.1158/1078-0432.CCR-12-0077-T.
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. [Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial]. 2017 Aug 01;127(8):2930–2940. doi:10.1172/JCI91190.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545–15550. doi:10.1073/pnas.0506580102.
   PubMed Web of Science ®Google Scholar
• Tan TZ, Rouanne M, Tan KT, Huang RY, Thiery JP. molecular subtypes of urothelial bladder cancer: results from a meta-cohort analysis of 2411 tumors. Eur Urol. [Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov’t]. 2019 Mar 01;75(3):423–432.
   Google Scholar
• Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf. [Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov’t]. 2013;14:7. doi:10.1186/1471-2105-14-7.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Zitvogel L, Sautès Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717–734. doi:10.1038/nrclinonc.2017.101.
   PubMed Web of Science ®Google Scholar
• Fu H, Zhu Y, Wang Y, Liu Z, Zhang J, Xie H, Fu Q, Dai B, Ye D, Xu J et al. Identification and validation of stromal immunotype predict survival and benefit from adjuvant chemotherapy in patients with muscle-invasive bladder cancer. Clin Cancer Res. 2018 Jul 01;24(13):3069–3078. doi:10.1158/1078-0432.CCR-17-2687.
   PubMed Web of Science ®Google Scholar
• Henrique R, Nunes SP, Jeronimo C. MSH2 Expression and Resistance to Cisplatin in Muscle-invasive Bladder Cancer: A Mix of Progress and Challenges. EUR UROL. [Editorial; Comment]. 2019 Feb 01;75(2):251–252. doi:10.1016/j.eururo.2018.11.014.
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Kryukov GV, O’Connor KW et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014 Oct 01;4(10):1140–1153. doi:10.1158/2159-8290.CD-14-0623.
   PubMed Web of Science ®Google Scholar
• Liu D, Plimack ER, Hoffman-Censits J, Garraway LA, Bellmunt J, Van Allen E, Rosenberg JE. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol. [Letter; Validation Studies]. 2016;2(8):1094–1096. doi:10.1001/jamaoncol.2016.1056.
   PubMed Web of Science ®Google Scholar
• Schneider AK, Chevalier MF, Derré L. The multifaceted immune regulation of bladder cancer. Nature reviews. Urology. 2019 Jan 01;16(10):613–630. doi:10.1038/s41585-019-0226-y.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhu Y, Xu L, Zhang J, Xie H, Fu H, Zhou Q, Chang Y, Dai B, Xu J, et al. Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer. ONCOIMMUNOLOGY. [Journal Article]. 2018 Jan 20;7(9):e1474317. doi:10.1080/2162402X.2018.1474317.
   PubMed Web of Science ®Google Scholar
• Zhou L, Xu L, Chen L, Fu Q, Liu Z, Chang Y, Lin Z, Xu J. Tumor-infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer. ONCOIMMUNOLOGY. 2017 Jan 01;6(4):e1293211. doi:10.1080/2162402X.2017.1293211.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Fu Q, Chang Y, Liu Z, Zhang J, Xu L, Zhu Y, Wang Y, Zhang W, Xu J, et al. CD19+ tumor-infiltrating B-cells prime CD4+ T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer. Cancer Immunol Immunother. 2019;68(1):45–56. doi:10.1007/s00262-018-2250-9.
   PubMed Web of Science ®Google Scholar
• Mathieu R, Lucca I, Roupret M, Briganti A, Shariat SF. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nat Rev Urol. [Journal Article; Review]. 2016;13(8):471–479. doi:10.1038/nrurol.2016.126.
   PubMed Web of Science ®Google Scholar
• Peters A, Burkett PR, Sobel RA, Buckley CD, Watson SP, Bettelli E, Kuchroo VK. Podoplanin negatively regulates CD4+ effector T cell responses. J Clin Invest. [Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov’t]. 2015;125(1):129–140. doi:10.1172/JCI74685.
   PubMed Web of Science ®Google Scholar
• Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee I-L et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014 Jan 01;25(2):152–165. doi:10.1016/j.ccr.2014.01.009.
   PubMed Web of Science ®Google Scholar